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Henoch-Schönlein Purpura (HSP) is the most frequent
children's vasculitis, predominant in male gender and
more often between the ages of 2 and 14 years.
The etiology is still unknown but generally it has a good
outcome.
The first event is typically a lower limb palpable purpura,
with involvement of the gut or kidney. The renal disease
usually appears in the first month, progressing to renal
insufficiency in about 5% to 20%.
The authors present a case of a male toddler, that soon
after birth, began with intermittent episodes of diffuse
erythematosus-maculopapular rash on the face, trunk and
upper limbs. These cutaneous manifestation where associ-
ated with transitory hematologic alterations and elevation
of serologic IgA, which resolved after a short period of cor-
ticoids. Skin biopsy revealed vasculitis.
Ten years later, the child complained about unspecific
polyarthralgia and was referred to Pediatric Rheumatol-
ogy. He was normotense, without signs of arthritis, but
with diffuse erythematosus-maculopapular rash on the
face, trunk and upper limbs and macroscopic hematuria.
Kidney biopsy revealed IgA nephritis and the diagnosis of
HSP could be made. The treatment began using corticoid
and ACE inhibitors, because of persistent microalbu-
minuria.
He maintains the renal function stabilized, but complains
of recidivant cutaneous lesions that require higher doses
of corticoid.
This clinical case relevance resides in the fact that these
recidivant cutaneous lesions are found in atypical regions
and that kidney involvement begun at a rather late period,
when generally is revealed in the first months of the dis-
ease onset.
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